Clinical Trial Update: Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in Patients With Junctional Epidermolysis Bullosa [Phase 2, Phase 3]

View source ↗

Summary

An open-label pivotal trial of autologous, gene-modified stem cell grafts for epidermis restoration in Junctional Epidermolysis Bullosa has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Junctional Epidermolysis Bullosa

Drugs mentioned

• Autologous grafts containing stem cells genetically modified for epidermis restoration

Snippet

Sponsor: Holostem s.r.l. | Conditions: Junctional Epidermolysis Bullosa Non-Herlitz Type | Phase 2, Phase 3 | Status: TERMINATED